Search This Blog

Thursday, May 15, 2025

UAE to build biggest AI campus outside US in Trump deal, bypassing past China worries

 The United Arab Emirates and the United States have signed an agreement for the Gulf country to build the largest artificial intelligence campus outside the United States, a type of deal that previously faced restrictions over Washington's concerns that China could access the technology.

The countries did not say which AI chips from Nvidia or other companies could be included in UAE data centres, but sources had said a deal would give the Gulf country expanded access to advanced AI chips. Nvidia Chief Executive Jensen Huang was seen in televised footage conversing with U.S. President Donald Trump and UAE President Sheikh Mohamed bin Zayed Al Nahyan at a palace in Abu Dhabi on Thursday. 

Such a long-coveted deal, finalised during Trump's visit to Abu Dhabi on Thursday, is a major win for the UAE, which has been trying to balance its relations with its longtime ally the U.S. and its largest trading partner China. It reflects the Trump administration's confidence that the chips can be managed securely, in part by requiring data centres be managed by U.S. companies.

The UAE, a major oil producer, has been spending billions of dollars in a push to become a global AI player. But its ties to China had limited access to U.S. chips under former President Joe Biden.

The AI agreement "includes the UAE committing to invest in, build, or finance U.S. data centres that are at least as large and as powerful as those in the UAE," the White House said. 

"The agreement also contains historic commitments by the UAE to further align their national security regulations with the United States, including strong protections to prevent the diversion of U.S.-origin technology."

Reuters had earlier reported that the two countries had finalised a technology framework agreement and that it would require commitments on both sides to the security of the technology.

The UAE could be allowed to import 500,000 of Nvidia's most advanced AI chips per year starting in 2025, sources have told Reuters. Nvidia declined to comment. The UAE foreign ministry did not immediately respond to a request for comment.

Central to the agreement announced on Thursday is the 10 square mile (25.9 square kilometre) AI campus in Abu Dhabi with 5 gigawatts of power capacity for AI data centres, the U.S. Commerce Department said.

"That's bigger than all other major AI infrastructure announcements we've seen so far," Rand Corporation analyst Lennart Heim said on X. That is enough power to support 2.5 million of Nvidia's top-line B200 chips, he calculated.

The campus will be built by Abu Dhabi state-backed firm G42, but U.S. Secretary of Commerce Howard Lutnick said in a release that "American companies will operate the data centers and offer American-managed cloud services throughout the region."

The U.S. fact sheets also described chip company Qualcomm working on an AI-related engineering centre and that Amazon Web Services, the cloud unit of the tech and commerce company, would work with local partners on cybersecurity and fostering cloud adoption.

EASING RELATIONS

The U.S. has pursued protectionist policies for years to curb China's access to advanced semiconductors, including ensuring the chips do not end up in the country via third parties.

Regulations are easing under Trump, whose AI czar David Sacks said in Riyadh on Tuesday that the Biden administration's export controls were "never intended to capture friends, allies, strategic partners".

Granting the UAE more access to the most advanced chips, manufactured by firms such as Nvidia, marks a major turnaround.

"This shift enables (the UAE) to deepen its technology partnership with the U.S. while still preserving trade ties with China," said Mohammed Soliman, senior fellow at the Middle East Institute.

"It doesn't mean abandoning China but it does mean recalibrating tech strategy to align with U.S. standards and protocols where it matters most: compute, cloud, and chip supply chains," he said.  

AI was top of the agenda when UAE President Sheikh Mohamed bin Zayed Al Nahyan visited Washington in December in the final days of Joe Biden's presidency. G42 and MGX, the state-linked vehicles picked to drive the UAE's AI investment push, have also invested in U.S. firms such as OpenAI and Elon Musk's xAI, while Microsoft last year agreed to invest $1.5 billion in G42.

The two companies said the deal was backed by security assurances, and under U.S. pressure, G42 had previously begun ripping out Chinese hardware it was using and sold off Chinese investments.

Still, major Chinese firms like Huawei and Alibaba Cloud are present in the UAE, and organised AI chip smuggling to China was tracked out of countries including Malaysia, Singapore and the UAE, a source told Reuters in February.  

https://www.msn.com/en-ca/money/topstories/uae-to-build-biggest-ai-campus-outside-us-in-trump-deal-bypassing-past-china-worries/ar-AA1ERkEr

RFK Jr. aide: GLP-1 weight loss meds will cost same in US as in least costly countries

 Aide to RFK Jr. says White House is pushing for global price parity on GLP-1 drugs for weight loss

https://seekingalpha.com/news/4449223-rfk-jr-aide-glp-1-weight-loss-meds-will-cost-same-as-in-least-expensive-countries

Doximity Stock Drops 20% After Outlook Disappoints

 Shares of Doximity plummeted late Thursday after the telehealth software company dished out a disappointing outlook.

Doximity (DOCS) stock was recently down more than 20%. The company after Thursday's closing bell said revenue for the quarter ending June 30 was seen coming in between $139 and $140 million, while full-year revenue was expected at $619 million to $631 million.1 The high end of both ranges was below the current mean estimate as tracked by Visible Alpha.

The company's current-quarter and full-year guidance for adjusted EBITDA also disappointed investors.

Doximity's shares had fallen nearly 2% on Thursday, leaving them up about 9% for the year so far. A fall like the one seen after hours tonight would return them to levels not seen since the fall.

Doximity said fiscal fourth-quarter sales for the quarter ended March 30 rose 17% to $138.3 million, with subscription revenue rising by a similar percentage. "We closed out fiscal 2025 on a high note, with record engagement, strong profits," CEO Jeff Tangney said in a statement.

https://www.investopedia.com/doximity-stock-drops-20-percent-after-outlook-disappoints-11736034

Walmart’s former U.S. CEO thinks retailer can absorb tariff costs, hits ‘doom and gloom’ comment

 Walmart

’s business is strong enough to withstand tariff headwinds without increasing its prices, according to the discount retailer’s former U.S. CEO.

Bill Simon, who ran Walmart U.S. from 2010 to 2014, suggests the company may be overstating challenges tied to tariffs.

“If you look down deep and dig into the details of their earnings release today, you know this quarter they grew their gross profit margin in the U.S. business 25 basis points. So, they’re expanding their margin. They also reported their general merchandise categories were flattish because they had mid-single digit price deflation,” he told CNBC’s “Fast Money” on Thursday, the day Walmart reported fiscal first-quarter results. “That sort of gives them room in my view to manage any tariff impact that they would have.”

Simon is optimistic consumers can largely handle price increases — citing a steady jobs market and cheaper fuel prices this year. But he notes worrisome commentary from corporate executives could be chipping away at consumer confidence.

“All the doom and gloom we hear about price increases and tariffs like we heard from my friends at Walmart today, I think it scares them some,” said Simon, who’s now on the Darden Restaurants board and is the chairman at Hanesbrands.

Walmart

 shares fell 0.5% on Thursday, but the stock closed above session lows. Shares are off almost 9% from the all-time high of $105.30 hit on Feb. 14.

On Feb. 20, Simon joined “Fast Money” as Walmart shares were wrapping up their worst week since May 2022 on tariff jitters. He suggested the stock was a steal for investors even though Walmart warned profits were slowing.

As of Thursday’s close, Walmart shares are positive for the year, up more than 6% in 2025. The stock has climbed more than 7% since President Donald Trump’s tariff announcement on April 2.

https://www.cnbc.com/2025/05/15/walmart-can-absorb-tariffs-fmr-us-ceo-simon-questions-price-hikes.html

Montana Becomes Latest State To Ban Lab-Grown Meat

 On Tuesday, Montana State Governor Greg Gianforte announced that he had signed a bill into law banning the manufacturing and sale of lab-grown meat

"So-called "lab-grown meat" has no place in Montana," Gov. Gianforte wrote on X, adding, "By signing HB 401 into law, I am proud to defend our way of life and the hardworking Montana ranchers who produce the best beef in the world."

Montana is now the fifth state in the nation to pass legislation prohibiting lab-cultivated proteins. The push comes after concurrent Biden-era policies that simultaneously created a loophole for safety testing while prioritizing lab-cultivated proteins as "Climate-Friendly" ahead of labeling requirements. 

Not exactly a drug, but not necessarily food harvested in nature, in 2019, Congress directed the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) to establish a formal agreement delineating each agency's responsibilities for regulating lab-made or "cellular-cultivated" meat.

By early 2021, the Biden administration prioritized lab-made meat products as a "Climate-Smart" Agricultural alternative, promising a fast track to manufacturers Good Meat Inc and the Bill Gates-backed Upside Foods.

By 2023, the FDA had issued a "No Questions Asked" approval for lab-cultivated "chicken cells with characteristics of fibroblasts." 

While the USDA does not regulate processed food, the agreement stipulated that the USDA's Food Safety Inspection Service (FSIS) would be handed off regulatory oversight "at the point of harvest." 

Bureaucratic translation: The USDA's regulatory role would be limited to "labeling and sanitation." 

While sanitation seems fairly straightforward, it's the labeling requirement - which has yet to materialize - that has state lawmakers pumping the brakes.

Since early 2020, FSIS has gone round-after-round with "stakeholders" about what to call this petri-dish creation. During the last round of "name the thingamajig" stakeholders warned the FSIS that transparent labeling would "hamper innovation," and "violate the First Amendment."

To-date, the USDA has not fulfilled its regulatory role, according to the delineated agreement. To be fair, the FDA didn't exactly uphold its end of the bargain either with fast-tracked "No Questions" approvals. 

Even as whistleblowers were equating lab-made meats to the next Theranos, the "Big 4" meat packers began rapidly investing billions to replace ranchers with biotech.

With the FDA's blessing and zero red tape requiring transparent labeling, companies like JBS, Tyson, and Cargill have quickly begun producing lab-grown beef, cultured chicken, pork, fish, sausages, burgers, meatballs, and other prepared foods.

While some argue that state-level bans harm the free market, local lawmakers see them as part of a larger fight to preserve Western values.

"Agriculture is our state's number one industry, and this bill takes a clear stand to protect our ranchers and our food supply," Montana State Rep. Braxton Mitchell said. "We won't let synthetic products with misleading labels undercut the hard work of Montana's farm and ranch families."

https://www.zerohedge.com/food/montana-becomes-latest-state-ban-lab-grown-meat

Rite Aid Says It Enters Into Series Of Sale Transactions To Ensure Continuity Of Care

 Rite Aid Corporation ("Rite Aid" or the "Company") today announced that it has successfully entered into a series of sale agreements and pharmacy services transition agreements. This includes the rolling transition of pharmacy assets from more than 1,000 store locations across the U.S. to operators including CVS Pharmacy, Walgreens, Albertsons, Kroger, and Giant Eagle, among others, as well as the sale and operation by CVS Pharmacy of many Rite Aid and Bartell Drugs stores located in Washington, Oregon, and Idaho.

Importantly, during the transition, Rite Aid stores will remain open, and customers can continue to access their pharmacy services, including prescription refills and immunizations, without interruption.

Matt Schroeder, Chief Executive Officer of Rite Aid, said, "A key priority for Rite Aid is to ensure that as many of our loyal customers as possible continue to receive the pharmacy services and care they require without interruption. These agreements ensure our pharmacy customers will experience a smooth transition while preserving jobs for some of our valued team members."

The sale transactions are subject to approval by the U.S. Bankruptcy Court for the District of New Jersey (the "Court"). The Court is currently scheduled to conduct a hearing to approve the sales on May 21, 2025. Upon approval from the Court, the sales will remain subject to certain regulatory notices and approvals, and other customary closing conditions.

https://uk.finance.yahoo.com/news/rite-aid-enters-series-sale-224000231.html

Amgen owes $406 million for monopolizing cholesterol drug market, US jury says

 A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its cholesterol-reduction drug Repatha at the expense of Regeneron's rival drug Praluent.

The jury agreed with Regeneron that Amgen unlawfully bundled Repatha with two of its blockbuster anti-inflammatory drugs to persuade pharmacy benefit managers to buy it instead of Praluent.

The verdict includes $271.2 million for Regeneron in punitive damages. Amgen said in a statement that it "has always competed fairly and in compliance with the antitrust laws" and "look[s] forward to post-trial proceedings."

"Larger companies should not be allowed to use anticompetitive tactics to push competitors out of the market," Regeneron CEO Leonard Schleifer said in a statement.

Tarrytown, N.Y.-based Regeneron filed the lawsuit in 2022, accusing Amgen of engaging in an anticompetitive scheme to drive Amgen's drug out of the market. Thousand Oaks, California-based Amgen denied the allegations and countered that Regeneron's business decisions caused lost Praluent sales.

Regeneron earned more than $241 million from sales of Praluent in the U.S. last year, while Amgen made over $1.1 billion from U.S. Repatha sales, according to company reports.

https://www.marketscreener.com/quote/stock/AMGEN-INC-4847/news/Amgen-owes-406-million-for-monopolizing-cholesterol-drug-market-US-jury-says-49971103/